AGER and neoplasm: Additionally, our research has managed to prove the therapeutic efficacy of a RAGE inhibitor, Azeliragon, through an innovative ex vivo assay of tumor fragments derived from the patient himself in parallel with its prospective phase I/II clinical trial (NCT05635734).